EUVIMEDEUVIMED entdecken
ValidierungsstudieMultizentrische Studie

Development and validation of a predictive model for early failure of biological therapy in perianal fistulizing Crohn’s disease based on three-dimensional transrectal ultrasound

Shi-Si Ding, Chang Liu, Guan-Qun Zhang, Wei-Wei Ren, Hui Zhao, Qian Zhang, Hao-Qiang Yin, Li-Ping Sun iD, Hui-Xiong Xu iD

Inflammatory Bowel Diseases · 01.08.2026 · 32 (8) · 1481-1494

DOI: 10.1093/ibd/izag048 ↗

Kurz gefasst

Validierungsstudie in der Zeitschrift Inflammatory Bowel Diseases, online erschienen am 23.04.2026. Verfasst von Shi-Si Ding und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Ultrasound, Center of Minimally Invasive Treatment for Tumor, Shanghai Tenth People's Hospital, School of Medicine, Tongji Univ…. Hauptthemen laut MEDLINE: Crohn Disease, Rectal Fistula, Imaging, Three-Dimensional. Die Arbeit nennt 29 Literaturangaben. Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance Despite the clinical use of three-dimensional transrectal ultrasound (3D-TRUS) in pfCD, no validated model exists to predict early biologic treatment failure.

Objective

Our objective was to develop and validate such a predictive model using 3D-TRUS-derived parameters.

Design

This study was a double-center retrospective study.

Setting

Patients with pfCD who underwent biologic therapy at two medical centers and completed both 3D-TRUS and magnetic resonance imaging (MRI) assessments prior to treatment initiation and at approximately 12 weeks post-treatment (range: 6-18 weeks) were included in the study.

Participants

A total of 102 patients were included in the analysis, with 80 patients from Hospital A formed the training/internal validation cohort; 22 from Hospital B comprised the external validation cohort. Exposure Biologic therapy for pfCD. Main Outcome(s) and Measure(s) The primary outcome was early treatment failure, defined as stable or aggravated disease (SD/AD) based on MRI criteria. Patients were divided into a failure group and a non-failure group. Predictive factors were identified using LASSO regression followed by multivariate logistic regression, and a nomogram was constructed based on the final model. Model performance was assessed through internal validation via the Bootstrap method (1000 resamples) and external validation.

Results

Multivariate analysis identified three independent predictors of early treatment failure (all P < .05): main fistula length ≥ 2 cm, inflammatory mass size > 2 cm, and internal orifice-anal margin distance (per 1-mm increase). The nomogram showed an AUC of 0.955 (95% CI: 0.915-0.995) in training cohort. Hosmer-Lemeshow confirmed good fit, and decision curve analysis (DCA) demonstrated clinical utility. Internal validation maintained an AUC of 0.955 (0.911-0.987). External validation yielded an AUC of 0.875 (0.700-1.000), with DCA supporting clinical applicability. Conclusions and Relevance 3D-TRUS features effectively predict early biologic failure in pfCD. The nomogram provides a tool for risk assessment to guide clinical decisions regarding treatment escalation or switch, supporting more individualized patient management.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Crohn DiseaseRectal FistulaImaging, Three-DimensionalHumansRetrospective StudiesMaleFemaleTreatment FailureUltrasonographyAdultNomogramsMagnetic Resonance ImagingRectumMiddle AgedPredictive Value of Tests

Stichwörter der Autor:innen

Crohn’s diseaserectal fistulathree-dimensional imagingtreatment outcomeultrasonography

Autor:innen und Institutionen

  • Department of Medical Ultrasound, Center of Minimally Invasive Treatment for Tumor, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai 200072, China.
  • Ultrasound Research and Education Institute, Clinical Research Center for Interventional Medicine, School of Medicine, Tongji University, Shanghai 200072, China.
  • Shanghai Engineering Research Center of Ultrasound Diagnosis and Treatment, National Clinical Research Center for Interventional Medicine, Shanghai 200072, China.
  • Department of Medical Ultrasound, Longhua Hospital Shanghai University of Traditional Chinese Medicine, Shanghai 200032, China.
  • Department of Ultrasound, Institute of Ultrasound in Medicine and Engineering, Zhongshan Hospital, Fudan University, Shanghai 200032, China.

ORCID-Profile: Li-Ping Sun, Hui-Xiong Xu

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Ding, S. S., Liu, C., Zhang, G. Q., Ren, W. W., Zhao, H., Zhang, Q., Yin, H. Q., Sun, L. P., & Xu, H. X. (2026). Development and validation of a predictive model for early failure of biological therapy in perianal fistulizing Crohn’s disease based on three-dimensional transrectal ultrasound. Inflammatory Bowel Diseases, 32(8), 1481-1494. https://doi.org/10.1093/ibd/izag048

Vancouver

Ding SS, Liu C, Zhang GQ, Ren WW, Zhao H, Zhang Q, et al. Development and validation of a predictive model for early failure of biological therapy in perianal fistulizing Crohn’s disease based on three-dimensional transrectal ultrasound. Inflammatory Bowel Diseases. 2026;32(8):1481-1494. doi:10.1093/ibd/izag048

BibTeX
@article{Ding2026,
  author = {Ding, Shi-Si and Liu, Chang and Zhang, Guan-Qun and Ren, Wei-Wei and Zhao, Hui and Zhang, Qian and Yin, Hao-Qiang and Sun, Li-Ping and Xu, Hui-Xiong},
  title = {Development and validation of a predictive model for early failure of biological therapy in perianal fistulizing Crohn’s disease based on three-dimensional transrectal ultrasound},
  journal = {Inflammatory Bowel Diseases},
  year = {2026},
  volume = {32},
  number = {8},
  pages = {1481--1494},
  doi = {10.1093/ibd/izag048}
}
Kostenlos starten →